Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms.
作者信息
Yanez Betina, Bouchard Laura C, Cella David, Sosman Jeffrey A, Kircher Sheetal M, Mohindra Nisha A, Cristofanilli Massimo, Penedo Frank J
机构信息
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
出版信息
Cancer. 2019 Jul 15;125(14):2338-2344. doi: 10.1002/cncr.32030. Epub 2019 Apr 29.
Abstract
摘要
相似文献
1
Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms.肿瘤新一代测序与免疫治疗新时代以患者为中心的参与及症状/毒性监测：OncoTool和OncoPRO平台
Cancer. 2019 Jul 15;125(14):2338-2344. doi: 10.1002/cncr.32030. Epub 2019 Apr 29.
2
Patient Involvement as a Means to Improving Care Quality.患者参与作为提高医疗质量的一种手段。
Dtsch Arztebl Int. 2015 Oct 2;112(40):663-4. doi: 10.3238/arztebl.2015.0663.
3
Individualized Patient-Centered Care: A Physician Assistant Curriculum in Information Mastery, Clinical Reasoning, and Shared Decision Making.以患者为中心的个性化医疗：医师助理信息掌握、临床推理与共同决策课程
J Physician Assist Educ. 2017 Sep;28(3):158-163. doi: 10.1097/JPA.0000000000000139.
4
'That's the doctor's job': Overcoming patient reluctance to be involved in medical decision making.“那是医生的工作”：克服患者参与医疗决策的抵触情绪。
Patient Educ Couns. 2017 Jan;100(1):14-17. doi: 10.1016/j.pec.2016.07.010. Epub 2016 Jul 4.
5
On listening.在听诊时。
Cancer. 2020 Jan 1;126(9):1828-1831. doi: 10.1002/cncr.32729. Epub 2020 Jan 22.
6
Reconsidering patient participation in guideline development.重新思考患者参与指南制定。
Health Care Anal. 2009 Sep;17(3):198-216. doi: 10.1007/s10728-008-0099-3. Epub 2008 Dec 20.
7
Shared decision making in hypertension.
Fam Pract. 2002 Jun;19(3):310. doi: 10.1093/fampra/19.3.310.
8
Person-centred analysis in physician-patient relationship.医患关系中的以患者为中心的分析。
Eur J Intern Med. 2017 Sep;43:e26-e27. doi: 10.1016/j.ejim.2017.05.014. Epub 2017 May 23.
9
Choosing Wisely Canada recommendations.加拿大明智选择推荐意见。
Can Fam Physician. 2019 Feb;65(2):116.
10
Dilemmas in patient centeredness and shared decision making: a case for vulnerability.以患者为中心和共同决策中的困境：一个关于脆弱性的案例。
Patient Educ Couns. 2006 Sep;62(3):291-8. doi: 10.1016/j.pec.2006.06.012. Epub 2006 Jul 21.
引用本文的文献
1
Patient-reported outcome measure (PROM) programs for monitoring symptoms among patients treated with immunotherapy: a scoping review.用于监测接受免疫治疗患者症状的患者报告结局指标（PROM）项目：一项范围综述
JNCI Cancer Spectr. 2024 Nov 1;8(6). doi: 10.1093/jncics/pkae102.
2
Living with Metastatic Cancer: A Roadmap for Future Research.与转移性癌症共存：未来研究路线图
Cancers (Basel). 2020 Dec 8;12(12):3684. doi: 10.3390/cancers12123684.
3
Optimizing Health Information Technologies for Symptom Management in Cancer Patients and Survivors: Usability Evaluation.优化癌症患者及幸存者症状管理的健康信息技术：可用性评估
JMIR Form Res. 2020 Sep 21;4(9):e18412. doi: 10.2196/18412.
4
The increasing value of eHealth in the delivery of patient-centred cancer care.电子健康在提供以患者为中心的癌症护理方面的价值不断增加。
Lancet Oncol. 2020 May;21(5):e240-e251. doi: 10.1016/S1470-2045(20)30021-8.
5
Innovations in research and clinical care using patient-generated health data.利用患者生成的健康数据进行研究和临床护理的创新。
CA Cancer J Clin. 2020 May;70(3):182-199. doi: 10.3322/caac.21608. Epub 2020 Apr 20.
本文引用的文献
1
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.多中心癌症临床试验中患者报告症状性不良事件的可行性评估。
JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.
2
Discussing molecular testing in oncology care: Comparing patient and physician information preferences.探讨肿瘤护理中的分子检测：比较患者和医生的信息偏好。
Cancer. 2017 May 1;123(9):1610-1616. doi: 10.1002/cncr.30494. Epub 2017 Jan 31.
3
Cardiovascular Toxic Effects of Targeted Cancer Therapies.靶向癌症治疗的心血管毒性作用
N Engl J Med. 2016 Oct 13;375(15):1457-1467. doi: 10.1056/NEJMra1100265.
4
The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials.肿瘤临床试验中进行毒性分析的新方法势在必行。
J Natl Cancer Inst. 2015 Aug 1;107(10). doi: 10.1093/jnci/djv216. Print 2015 Oct.
5
NCI-MATCH launch highlights new trial design in precision-medicine era.美国国立癌症研究所MATCH计划启动凸显精准医学时代的新试验设计。
J Natl Cancer Inst. 2015 Jul 3;107(7). doi: 10.1093/jnci/djv193. Print 2015 Jul.
6
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.大规模基因组检测以促进纳入基因组匹配临床试验的可行性。
J Clin Oncol. 2015 Sep 1;33(25):2753-62. doi: 10.1200/JCO.2014.60.4165. Epub 2015 May 26.
7
Toxicities of Immunotherapy for the Practitioner.从业者的免疫治疗毒性
J Clin Oncol. 2015 Jun 20;33(18):2092-9. doi: 10.1200/JCO.2014.60.0379. Epub 2015 Apr 27.
8
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.抗癌治疗期间出现的有症状毒性：三项随机试验中患者报告和医生报告的一致性。
J Clin Oncol. 2015 Mar 10;33(8):910-5. doi: 10.1200/JCO.2014.57.9334. Epub 2015 Jan 26.
9
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）的制定。
J Natl Cancer Inst. 2014 Sep 29;106(9). doi: 10.1093/jnci/dju244. Print 2014 Sep.
10
Genomic testing in cancer: patient knowledge, attitudes, and expectations.癌症的基因组检测：患者的知识、态度和期望。
Cancer. 2014 Oct 1;120(19):3066-73. doi: 10.1002/cncr.28807. Epub 2014 Jun 24.
Zotero 插件